Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors

Bortezomib and the other licensed 20S proteasome inhibitors show robust activity against liquid tumors like multiple myeloma, but have disappointed against solid tumors including ovarian cancer. Consequently, interest is mounting in alternative non-peptide based drugs targeting the proteasome's...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one 2021-09, Vol.16 (9), p.e0256937-e0256937
Hauptverfasser: Anchoori, Ravi K, George, Logan, Tseng, Ssu-Hsueh, Lam, Brandon, Polkampally, Srinidhi, Amiano, Anjali D, Foran, Palmer, Tsingine, Hannah, Samanapally, Harideep, Carrizo Velasquez, Fernanda, Das, Samarjit, Xing, Deyin, Bin Salam, Ahmad, Karanam, Balasubramanyam, Hung, Chien-Fu, Roden, Richard B S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!